| 2003 . | Heterozygote pathologic mutation in the transthyretin gene (p.Gly67Ala) confirmed. . |
|---|---|
| 2012 | Onset of variant transthyretin amyloidosis (ATTRv) neuropathy symptoms. |
| February 2012 to October 2018 | Tafamidis therapy for neuropathy. |
| 2013–18 | Annually repeated transthoracic echocardiography depicting progressive septal |
| left ventricular (LV) hypertrophy and mild diastolic dysfunction. | |
| 2017–18 | Cardiovascular magnetic resonance (CMR) depicting non-ischaemic late gadolinium enhancement in the septum and basal LV myocardium suggestive of cardiac amyloidosis. |
| November 2018 to May 2019 | Inotersen therapy for neuropathy. |
| June 2019—Present | Patisiran therapy for neuropathy. |
| July 2019 | Occurrence of symptomatic, paroxysmal, tachycardic atrial fibrillation. |
| July 2019 | Repeated CMR (with vasodilalator–stress perfusion) showing no progression of cardiomyopathy and excluding myocardial ischaemia. No coronary stenosis on invasive angiography. |
| July 2019 | Implantation of a dual-chamber, MRI-conditional pacemaker (Medtronic Ensura DR MRI) due to a marked first-degree atrio-ventricular block (AV-block) (PQ interval up to 500 ms) with intermittent second-degree AV-block (2:1 conduction) under beta-blocker therapy. |
| September 2020 (Present) | Index cardiac evaluation, including CMR showing a relatively accelerated and unexpected improvement of cardiomyopathy findings. |
| 2003 . | Heterozygote pathologic mutation in the transthyretin gene (p.Gly67Ala) confirmed. . |
|---|---|
| 2012 | Onset of variant transthyretin amyloidosis (ATTRv) neuropathy symptoms. |
| February 2012 to October 2018 | Tafamidis therapy for neuropathy. |
| 2013–18 | Annually repeated transthoracic echocardiography depicting progressive septal |
| left ventricular (LV) hypertrophy and mild diastolic dysfunction. | |
| 2017–18 | Cardiovascular magnetic resonance (CMR) depicting non-ischaemic late gadolinium enhancement in the septum and basal LV myocardium suggestive of cardiac amyloidosis. |
| November 2018 to May 2019 | Inotersen therapy for neuropathy. |
| June 2019—Present | Patisiran therapy for neuropathy. |
| July 2019 | Occurrence of symptomatic, paroxysmal, tachycardic atrial fibrillation. |
| July 2019 | Repeated CMR (with vasodilalator–stress perfusion) showing no progression of cardiomyopathy and excluding myocardial ischaemia. No coronary stenosis on invasive angiography. |
| July 2019 | Implantation of a dual-chamber, MRI-conditional pacemaker (Medtronic Ensura DR MRI) due to a marked first-degree atrio-ventricular block (AV-block) (PQ interval up to 500 ms) with intermittent second-degree AV-block (2:1 conduction) under beta-blocker therapy. |
| September 2020 (Present) | Index cardiac evaluation, including CMR showing a relatively accelerated and unexpected improvement of cardiomyopathy findings. |
| 2003 . | Heterozygote pathologic mutation in the transthyretin gene (p.Gly67Ala) confirmed. . |
|---|---|
| 2012 | Onset of variant transthyretin amyloidosis (ATTRv) neuropathy symptoms. |
| February 2012 to October 2018 | Tafamidis therapy for neuropathy. |
| 2013–18 | Annually repeated transthoracic echocardiography depicting progressive septal |
| left ventricular (LV) hypertrophy and mild diastolic dysfunction. | |
| 2017–18 | Cardiovascular magnetic resonance (CMR) depicting non-ischaemic late gadolinium enhancement in the septum and basal LV myocardium suggestive of cardiac amyloidosis. |
| November 2018 to May 2019 | Inotersen therapy for neuropathy. |
| June 2019—Present | Patisiran therapy for neuropathy. |
| July 2019 | Occurrence of symptomatic, paroxysmal, tachycardic atrial fibrillation. |
| July 2019 | Repeated CMR (with vasodilalator–stress perfusion) showing no progression of cardiomyopathy and excluding myocardial ischaemia. No coronary stenosis on invasive angiography. |
| July 2019 | Implantation of a dual-chamber, MRI-conditional pacemaker (Medtronic Ensura DR MRI) due to a marked first-degree atrio-ventricular block (AV-block) (PQ interval up to 500 ms) with intermittent second-degree AV-block (2:1 conduction) under beta-blocker therapy. |
| September 2020 (Present) | Index cardiac evaluation, including CMR showing a relatively accelerated and unexpected improvement of cardiomyopathy findings. |
| 2003 . | Heterozygote pathologic mutation in the transthyretin gene (p.Gly67Ala) confirmed. . |
|---|---|
| 2012 | Onset of variant transthyretin amyloidosis (ATTRv) neuropathy symptoms. |
| February 2012 to October 2018 | Tafamidis therapy for neuropathy. |
| 2013–18 | Annually repeated transthoracic echocardiography depicting progressive septal |
| left ventricular (LV) hypertrophy and mild diastolic dysfunction. | |
| 2017–18 | Cardiovascular magnetic resonance (CMR) depicting non-ischaemic late gadolinium enhancement in the septum and basal LV myocardium suggestive of cardiac amyloidosis. |
| November 2018 to May 2019 | Inotersen therapy for neuropathy. |
| June 2019—Present | Patisiran therapy for neuropathy. |
| July 2019 | Occurrence of symptomatic, paroxysmal, tachycardic atrial fibrillation. |
| July 2019 | Repeated CMR (with vasodilalator–stress perfusion) showing no progression of cardiomyopathy and excluding myocardial ischaemia. No coronary stenosis on invasive angiography. |
| July 2019 | Implantation of a dual-chamber, MRI-conditional pacemaker (Medtronic Ensura DR MRI) due to a marked first-degree atrio-ventricular block (AV-block) (PQ interval up to 500 ms) with intermittent second-degree AV-block (2:1 conduction) under beta-blocker therapy. |
| September 2020 (Present) | Index cardiac evaluation, including CMR showing a relatively accelerated and unexpected improvement of cardiomyopathy findings. |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
